PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-30.46%
Negative ROE while CRVO stands at 22.46%. Joel Greenblatt would investigate capital misallocation or uncompetitive positioning.
-14.93%
Negative ROA while CRVO stands at 17.86%. John Neff would check for structural inefficiencies or mispriced assets.
-17.88%
Both companies show negative ROCE. Martin Whitman would investigate if external factors hamper profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.